Michael G. Palfreyman, PhD, DSc, MRPharmS

Dr. Michael Palfreyman has more than four decades of successful drug discovery and development experience with two major pharmaceutical companies and several biotechnology companies. He is currently chief scientific officer at Amorsa Therapeutics, a director of Oculogics, and scientific advisor to Jasco Pharmaceuticals, and he is responsible for research and development diligence at Torrey Pines Investment Ventures. Previously he was chairman of Amakem Therapeutics and Opthakem, vice president of drug development and program management at EnVivo (now Forum) Pharmaceuticals, and senior vice president of research and development at Scriptgen (now Anadys) Pharmaceuticals. Michael also held executive positions at Marion Merrell Dow (MMD) Research Institute (now Sanofi), including vice president of research (North America), and was a key member of the team that developed DFMO (eflornithine). Prior to MMD, Michael was the head of biochemical pharmacology at Beecham Pharmaceuticals (now GlaxoSmithKline). He received his BPharm, MRPharmS, PhD, and DSc from the University of Nottingham. He is co-inventor on 45 US and European patents and three pending patents, and has coauthored over 150 scientific articles and book chapters.